63 results about "Peptide binding" patented technology

The present disclosure provides compositions and methods for conjugating a target polypeptide and a target oligonucleotide. More particularly, the present disclosure provides compositions and methods for making and using a recombinant protein harboring a domain recognizing a nucleic acid and a domain capable of binding and crosslinking with antigen-binding polypeptides.

Provided herein are computer-implemented methods of generating a disease map of a population. In some embodiments, the methods include applying a clustering algorithm to a set of weight and bias values of a trained electronic neural network to generate the disease map of the population. In some embodiments, the electronic neural network has been trained on training data that comprises representations of peptide sequence and binding value pair data sets obtained from reference subjects in the population in which a given peptide sequence and binding value pair data set comprises peptide sequence information and peptide binding values of antibodies to peptides that comprises the peptide sequence information. In some embodiments, the antibodies are from a sample obtained from a given reference subject in the population and are indicative of one or more disease states. Related systems, computer readable media, and additional methods are also provided.

The invention relates to the technical field of immune carriers, in particular to immune carrier microspheres loaded with individualized MHC-II binding polypeptide and vaccine preparation and application of the immune carrier microspheres loaded with the individualized MHC-II binding polypeptide. The core microsphere is loaded with individualized MHC-II binding polypeptide, the sequence of the MHC-II binding polypeptide is obtained by predicting and screening based on an HLA genotyping result, and each HLA allele corresponds to at least one high-affinity MHC-II binding polypeptide; and the shell is a glucan or other polymer coating layer. The preparation method has the advantages that the T epitope and the B epitope are separately subjected to immune competitive inhibition inside and outside the microspheres, so that a better immune effect is obtained. The antibody avoids cross reaction side effects; carrier molecule diversity is reduced, and side effects caused by T cell over-activation are avoided; th1 epitopes and Th2 epitopes can be contained in the microspheres, so that antibody immunity and T cell immunity functions are generated; the particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants.

An example composition includes one or more binding agents and one or more solid-phase substrates bound to the one or more binding agents. The one or more binding agents are or include: (i) a peptide including at least part of a full-length protein, where the peptide is for binding to an antibody, or (ii) a molecule that mimics an ability of the peptide to bind to the antibody.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The filed of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

Provided, as an anti-SARS-CoV-2 peptide drug, is an optimal salt form of a peptide that binds to a receptor-binding domain (RBD) in SARS-CoV-2.　A sodium or potassium salt of a peptide according to the present invention has, in a direction from an N-terminus to a C-terminus, a first region including a first helix and a second region including a second helix. The first region and the second region each include a site that binds to a receptor-binding domain (RBD) in SARS-CoV-2. A bond is formed between amino acid residues within five residues on the N-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the first region and amino acid residues within five residues on the C-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the second region, and the peptide binds to the receptor-binding domains (RBD) in SARS-CoV-2.

This invention relates to an antibacterial membrane-penetrating peptide and its applications. The amino acid sequence of the antibacterial membrane-penetrating peptide includes the sequence shown in SEQ ID NO.1 or a sequence with more than 70% homology to the sequence shown in SEQ ID NO.1. This invention screened and obtained a short peptide that specifically binds to the bacterial Hsp70s protein. It was found that this peptide binds to the Hsp70s protein through a traditional substrate-binding pocket, exhibiting an unusually high affinity for the protein in the DnaK-ATP state. The short peptide can inhibit Hsp70s protein activity to a certain extent, preventing it from aiding in the renaturation of denatured luciferase. Furthermore, while maintaining the integrity of the bacterial cell membrane, this short peptide has a superior ability to cross the bacterial cell membrane. The invention further discusses its application potential in the preparation of antibacterial drugs and antibiotic adjuvants, providing new ideas for solving current problems such as bacterial resistance and the difficulty in discovering new antibiotics.

This invention provides a simple method for evaluating whether or not a peptide binds to isovaleric acid. [Solution] A method for evaluating the binding affinity to isovaleric acid, comprising a preparation step of preparing a fluorescently labeled compound in which a fluorescent group is bonded to the α-carbon atom of isovaleric acid, and a contact step of contacting the fluorescently labeled compound with a peptide fragment of an olfactory receptor.

A deep learning-based method for predicting HLA-I binding to TCRs is proposed. This method collects comprehensive peptide-TCR binding records from four databases: IEDB, VDJdb, PIRD, and McPas-TCR, forming a dataset. The steps include: preprocessing the data before inputting it into the model to obtain a one-hot encoding matrix; inputting the one-hot encoding matrix into a deep learning model for learning, and predicting the binding probability. This invention can efficiently and accurately predict the binding affinity between TCRs and HLA-I complexes and requires only the CDR3β sequence.

The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.

The invention relates to the technical field of saccharomyces cerevisiae expression foreign protein, and discloses a saccharomyces cerevisiae strain with ASFV p14.5 displayed on the surface and a construction method and application thereof, and the method comprises the following steps: (1) synthesizing a delta site homologous arm sequence; (2) seamlessly connecting the homologous arm sequence of the delta site to a carrier pET23a, connecting a selective marker tryptophan biosynthetic gene TRP1 to the 5'end of the upstream homologous arm sequence of the delta site, and sequentially connecting an Aga2 gene, an E120R gene, a T2A peptide gene and an mCherry gene to the 5 'end; (3) carrying out enzyme digestion on two sides of the delta site through restriction endonuclease salI, and recovering a linearized fragment through agarose gel; and (4) integrating the recovered fragments into a host saccharomyces cerevisiae genome through a chemical conversion method, and culturing until bacterial colonies grow. The surface display type saccharomyces cerevisiae strain obtained by the invention not only has the stability of integrative saccharomyces cerevisiae for expressing foreign protein, but also can be used for more easily and more intuitively screening a high-expression quantity saccharomyces cerevisiae strain by combining the T2A peptide with mCherry.

The invention provides a bacterial outer membrane vesicle based on genetic engineering modification as well as preparation and application thereof, and relates to the technical field of biological medicines. According to the invention, through a genetic engineering technology, a bacterial outer membrane protein ClyA from escherichia coli W3110 is combined with a tumor killing peptide KLAK, and a recombinant plasmid ClyA-KLAK-pGEX-6P-1 for expressing a ClyA-KLAK fusion protein is constructed; the plasmid is transformed into W3110 escherichia coli to realize endogenous expression of the fusion protein, and the engineered outer membrane vesicles C-KLAK-OMVs with anti-tumor activity are successfully prepared. On the basis that the original morphology of the bacterial outer membrane vesicle is reserved, the anti-tumor activity of KLAK is also reserved, migration and invasion of tumor cells HGC27 and MDA-MB-231 can be remarkably inhibited, and apoptosis of the tumor cells HGC27 and MDA-MB-231 is promoted; meanwhile, the medicine loading potential is realized; in addition, the C-KLAK-OMVs also improves the problem of insufficient stability of the KLAK peptide in serum, and provides a new thought and reference for targeted therapy of tumors.

The present invention relates to a composition for alleviating hair loss or promoting hair growth, and more particularly, to a composition including an active ingredient in a liposome to which a PTD peptide and palmitoyl pentapeptide-4 are bound, and thus capable of effectively delivering the active ingredient into the skin, and having an excellent hair loss alleviation or hair growth promotion effect.

The application provides a preparation method of a stem cell exosome composition and application of the stem cell exosome composition in male sexual dysfunction, and the preparation method comprises the following steps: extracting stem cell exosomes; combining the stem cell exosomes with a stabilizing peptide; and preparing a stem cell exosome hydrogel; the stabilizing peptide comprises an amino acid sequence as shown in SEQ ID NO: 1. The stem cell exosome composition obtained by the method can improve the stability of the exosomes, improve the in-vivo bioavailability, prevent and relieve testicular injury, and inhibit inflammatory reactions.

The invention discloses a method for constructing an anti-spinetoram neoseiulus californicus gene and an ovary targeting peptide of the anti-spinetoram neoseiulus californicus gene. According to the invention, a segment of yolk protein targeted peptide binding region is identified in Neoseiulus californicus, and the yolk protein targeted peptide binding region and a Cas9 sequence are fused and constructed on a PET28a carrier, and the NcvgP2C-Cas9 protein is obtained through prokaryotic expression. NcvgP2C-Cas9 protein, sgNcnAChR alpha 6 and an endosome escape reagent are mixed and injected into female adult mites, NcnAChR alpha 6 gene large fragment deleted neoseiulus californicus offspring is obtained and shows a phenotype with 23.2 times of resistance to spinetoram, and the resistance of a knockout strain to the spinetoram belongs to an autosome partial recessive genetic mode. The invention provides a new method for the genetic improvement of the drug resistance of Neoseiulus californicus, and enhances the compatibility between biological control and pesticide treatment strategies.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention provides a composition and a method for treating a disease associated with amyloid deposits of Aβ in a patient's brain, such as Alzheimer's disease. Such a method involves administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of an antibody against Aβ. The immunogenic fragment comprises a linear or polyvalent peptide of Aβ. The pharmaceutical composition comprises an immunogenic fragment chemically linked to a carrier molecule that can be administered together with an ajuvant.

The present invention relates to a method of screening for peptides capable of binding to a ubiquitin protein ligase (E3), successful binding being determined by detecting the amount of a test protein in the cell. The invention relates to a method for determining if a peptide binds or is capable of binding to a ubiquitin protein ligase (E3) and thereby leads to degradation of a test protein, wherein the peptide is between about 7 and 110 amino acids in length, the method comprising: providing in a eukaryotic cell a candidate peptide functionally linked to a test protein, under conditions enabling ubiquitination of proteins by an E3; and detecting the amount of test protein present in the cell; whereby, a reduced amount of the test protein determines the candidate peptide as a peptide that binds or is capable of binding to an E3 (an E3-binding peptide).

Immunoglobulin light Chain "AL" amyloidosis is the most common form of systemic amyloidosis, accounting for approximately 70% of the diagnosed cases in developed countries. As there are treatments available, e.g., based on antibody C11-1F4, and in development for AL amyloidosis, there is a need in for more accurate methods for quality control of c11-1F4 antibodies or antigen-binding fragment thereof. Immunoassays, methods, and kits for testing the specificity of 11-1F4 antibodies are provided. The immunoassays, methods, and kits are more than 10 times more sensitive than the ELISA protocol that is routinely used for evaluation of c11-1F4 binding to LEN peptide.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

Provided herein are compounds comprising an isopeptide-linked lysine or an analog thereof. Further provided herein are methods for engineering peptide-binding proteins having increased affinity and / or selectivity for the compound according to the invention, as well as peptide-binding proteins with increased selectivity for the compound according to the invention. Moreover, methods for incorporating non-canonical amino acids into proteins are provided herein.

Are disclosed peptide binding the CD71 transferring receptor, genetically engineered DNA-binding proteins from starved cells (DPS), and hybrid protein-nucleic acid complexes having the capability of being identified and taken up by the human CD71 receptor, and which can be used in targeted delivery of nucleic acid in cells.

The invention relates to the technical field of biological medicine, in particular to a lung targeting peptide and application thereof in preparation of an extracellular vesicle drug delivery system. The amino acid sequence of the lung targeting peptide provided by the invention is as shown in SEQ ID NO. 2. The lung targeting peptide with alveolar epithelium targeting property is obtained through a phage display technology, the lung targeting peptide is combined to the surface of mesenchymal stem cell-derived extracellular vesicles (EVs), and the prepared targeting delivery system can act on lung epithelial cells more accurately and more long-acting, so that effective repair and protection of a lung barrier are realized. The invention provides an effective targeted delivery strategy for precise treatment of lung diseases, and has a good application prospect.

A computer-implemented method for identifying an amino acid sequence that is predicted to form a scaffold-binding peptide ligand that binds to a target, the method comprising: generating an amino acid sequence that describes a peptide, the sequence satisfying one or more predefined sequence constraints such that the peptide binds to one of one or more predefined scaffolds at at least two positions, thereby forming a scaffold-binding peptide ligand; determining at least one predicted interaction characteristic associated with an interaction between the peptide and one or more predefined targets; determining an advantage of the at least one predicted interaction characteristic; based on the determined advantageous, output data is provided that identifies one or more amino acid sequences that are predicted to form scaffold-binding peptide ligands that bind to the target.

The present technology generally relates to peptides that bind to the Eph receptor A2 (EphA2), to peptides that bind to the EphA2, and to compositions comprising such peptides.

The present invention relates to proteins, compositions and their use, wherein said protein comprises a first peptide having a first binding specificity, a second peptide having a second binding specificity and a linker, wherein said first and said second peptides bind at least one pathogen surface component and / or at least one molecule produced by a pathogen.

Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide / MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.